Potential treatment for psoriasis to be commercially developed under worldwide patent deal

Potential treatment for psoriasis to be commercially developed under worldwide patent deal

An anti-inflammatory peptide discovered by David Greaves and his group in the Dunn School will be tested for its ability to treat psoriasis following a licensing deal between the University of Oxford’s ISIS Innovation and San Francisco start-up Rogne Biosciences.

The company has raised over $1.5 million in seed financing to develop new, non-steroidal treatments for patients with mild to moderate psoriasis.

Professor Greaves explained: “Because the peptide will be applied to the skin and has a novel mode of action we expect to avoid the side-effects which trouble patients who use current injected psoriasis drugs or steroid creams. Our peptide is derived from a protein which is produced naturally by the human body and appears to play a role as the body’s own off-switch for inflammation.” 

For further on this story see:  
http://www.isis-innovation.com/news/news/IsisLicensesAnti-inflammatoryPeptidestoSanFranciscoStart-up.html

Thursday, August 7, 2014 - 08